Radiotherapy in localized stages of follicular and diffuse non-Hodgkin's lymphomas

Treatment with monoclonal antibodies, especially rituximab, is more and more frequent and questions the interest of radiotherapy in limited stages of diffuse B-cell large cell and follicular non-Hodgkin's lymphomas. From a review of literature, it appears that radiotherapy is of interest in bul...

Full description

Saved in:
Bibliographic Details
Published inCancer radiothérapie Vol. 20; no. 6-7; pp. 530 - 534
Main Authors Demoor-Goldschmidt, C, Agape, P, Barillot, I, Mahé, M A
Format Journal Article
LanguageFrench
Published France 01.10.2016
Subjects
Antineoplastic Agents - therapeutic use
Chemotherapy, Adjuvant
Humans
Lymphoma, Non-Hodgkin - pathology
Lymphoma, Non-Hodgkin - therapy
Radiotherapy Dosage
Radiotherapy, Adjuvant
Lymphomes B diffuse à grandes cellules
Diffuse B-cell lymphomas
Radiothérapie
Lymphomes folliculaires
Rituximab
Non-Hodgkin's lymphomas
Radiotherapy
Follicular lymphomas
Lymphomes non hodgkiniens
Online AccessGet full text

Cover

More Information
Summary:Treatment with monoclonal antibodies, especially rituximab, is more and more frequent and questions the interest of radiotherapy in limited stages of diffuse B-cell large cell and follicular non-Hodgkin's lymphomas. From a review of literature, it appears that radiotherapy is of interest in bulky disease, patients with incomplete metabolic response, elderly patients receiving short chemotherapy and those with recurrence after exclusive chemotherapy. Finally, this article gives recommendations on available techniques of radiotherapy and doses to be delivered.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1769-6658
DOI:10.1016/j.canrad.2016.07.090